Request Demo
Recent blog posts
Latest Hotspot
10 min read
Odontogenic myxoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Odontogenic myxoma indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Clear cell odontogenic carcinoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Clear cell odontogenic carcinoma strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
8 min read
Micron Biomedical Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Micron Biomedical BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Latest Hotspot
10 min read
Adenomatoid odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Adenomatoid odontogenic tumor strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Calcifying epithelial odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Calcifying epithelial odontogenic tumor strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Latest Hotspot
8 min read
Millendo Therapeutics Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Millendo Therapeutics Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Latest Hotspot
10 min read
Ameloblastoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Ameloblastoma indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Odontogenic keratocyst Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Odontogenic keratocyst strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
8 min read
Milestone Pharmaceuticals Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Milestone Pharmaceuticals Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Latest Hotspot
10 min read
Fibrous dysplasia of the jaw Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Fibrous dysplasia of the jaw strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Central giant cell granuloma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Central giant cell granuloma strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
8 min read
Microvascular Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Microvascular Therapeutics, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.